Recent developments in neuronal nicotinic acetylcholine receptor modulators

Bibliography

• SARGENT PB: The diversity of neuronal nicotinic ace- tylcholine receptors. Ann. Rev. Neurosci. (1993) 16:403–443.
   PubMed Web of Science ®Google Scholar
• UNWIN N: Nicotinic acetylcholine receptor at 9A reso-lution. J. Mol. Biol. (1993) 229:1101–1124.
   PubMed Web of Science ®Google Scholar
• UNWIN N: Projection structure of the nicotinic acetyl-choline receptor: distinct conformations of the a subunit. J Mol Biol. (1996) 257:586–596.
   PubMed Web of Science ®Google Scholar
• BOYD R: The molecular biology of neuronal nicotinic acetylcholine receptors. Grit. Rev. Toxicol. (1997) 27:299–318.
   PubMed Web of Science ®Google Scholar
• HOLLADAY M, DART M, LYNCH J: Neuronal nicotinic acetylcholine receptors as targets for drug discovery. J. Med. Chem. (1997) 40:4169–4194.
   PubMed Web of Science ®Google Scholar
• WONNACOTT S, DRASDO A, SANDERSON E, ROWELL P: Presynaptic nicotinic receptors and the modulation of transmission release. In: The Biology of Nicotine Depend-ence. Block J (Ed.), Wiley, Chichester (1990).
   Google Scholar
• NODA M, TAKAHASHI H, TANABE T et al.: Primary struc-ture of a-subunit precursor of Torpedo californica acetylcholine receptor deduced from cDNA sequence. Nature (1982) 299:793–797.
   PubMed Web of Science ®Google Scholar
• NODA M, TAKAHASHI H, TANABE T et al.: Primary struc-tures of 13- and 6-subunit precursors of Torpedo cali-fornica acetylcholine receptor deduced from cDNA sequences. Nature (1983) 301:251–255.
   PubMed Web of Science ®Google Scholar
• NODA M, TAKAHASHI H, TANABE T et al.: Structural ho-mology of Torpedo californica acetylcholine receptor subunits. Nature (1983) 302:528–553.
   PubMed Web of Science ®Google Scholar
• MISHINA M, KUROSAKI T, TOBIMATSU T et al.: Expres-sion of functional acetylcholine receptor from cloned cDNAs. Nature (1984) 307:604–608.
   PubMed Web of Science ®Google Scholar
• HEINEMANN S, BOULTER J, CONNOLLY J et al.: Molecular biology of muscle and neural acetylcholine receptors. In: Nicotinic Acetylcholine Receptors. Maelicke A (Ed.), Springer-Verlag, Berlin (1986).
   Google Scholar
• BOULTER J, EVANS K, GOLDMAN D et al.: Isolation of a cDNA clone coding for a possible neural nicotinic ace-tylcholine receptor a-subunit. Nature (1986) 319:368–374.
   PubMed Web of Science ®Google Scholar
• BOULTER J, CONNOLLY J, DENERIS E, GOLDMAN D, HEINEMANN S, PATRICK J: Functional expression of two neural nicotinic acetylcholine receptors from cDNA clones identifies a gene family. Proc. Nat. Acad. Sci. USA (1987) 84:7763–7767.
   PubMed Web of Science ®Google Scholar
• BOULTER J, O'SHEA-GREENFIELD A, DUVOISON RM et al.: a3, a5, and IA: three members of the rat neuronal nico-tinic acetylcholine receptor-related gene family form a gene cluster. J. Biol. Chem. (1990) 265:4472–4482.
   Google Scholar
• DENERIS E, CONNOLLY J, BOULTER J, WADA E, WADA K: Primary structure and expression of 13-2: a novel subunit of neuronal nicotinic acetylcholine receptors. Neuron (1988) 1:45–54.
   PubMedGoogle Scholar
• DENERIS E, BOULTER J, SWANSON L, PATRICK J, HEINE-MANN S: 133: a new member of nicotinic acetylcholine receptor gene family is expressed in brain. J. Biol. Chem. (1989) 264:6268–6272.
   PubMedGoogle Scholar
• DUVOISON RM, DENERIS ES, PATRICK J, HEINEMANN S:The functional diversity of the neuronal nicotinic ace-tylcholine receptors is increased by a novel subunit: IA. Neuron (1989) 3:487–496.
   PubMedGoogle Scholar
• ELGOYHEN AG, JOHNSON DS, BOULTER J, VETTER DE,HEINEMANN S: a9: an acetylcholine receptor with novel pharmacological properties expressed in rat cochlear hair cells. Cell (1994) 79:705–715.
   PubMed Web of Science ®Google Scholar
• LAMAR E, MILLER K, PATRICK J: Amplification of ge-nomic sequences identifies a new gene, alpha 6, in the nicotinic acetylcholine receptor gene family. Soc. Neu-rosci. Abs. (1990) 16:681.
   Google Scholar
• SCHOEPFER R, CONROY WG, WHITING P, GORE M, LIND-STROM J: Brain a-bungarotoxin binding protein cDNAs and mAbs reveal subtypes of this branch of the ligand-gated ion channel gene superfamily. Neuron (1990) 5:35–48.
   PubMed Web of Science ®Google Scholar
• WADA K, BALLIVET M, BOULTER J, CONNOLLY J, WADAE: Functional expression of a new pharmacological subtype of brain nicotinic acetylcholine receptor. Sci-ence (1988) 240:330–334.
   PubMed Web of Science ®Google Scholar
• GOLDMAN D, DENERIS E, LUYTEN W, KOCHLAR A, PAT-RICK J, HEINEMANN S: Members of a nicotinic acetyl-choline receptor gene family are expressed in different regions of the mammalian central nervous system. Cell (1987) 48:965–973.
   PubMed Web of Science ®Google Scholar
• MCGEHEE DS, ROLE LW: Physiological diversity of nico-tinic acetylcholine receptors expressed by vertebrate neurons. Ann. Rev. Physiol. (1995) 57:521–546.
   PubMed Web of Science ®Google Scholar
• WHITING P, SCHOEPFER R, LINDSTROM J, PRIESTLEY T:Structural and pharmacological characterization of the major brain nicotinic acetylcholine receptor sta-bly expressed in mouse fibroblasts. Mol. Pharmacol (1991) 40:463–472.
   PubMedGoogle Scholar
• GOPALAKRISHNAN M, MONTEGGIA L, ANDERSON D etal.: Stable expression, pharmacologic properties and regulation of the human neuronal nicotinic a4132 re-ceptor. J. Pharmacol. Exp. Ther. (1996) 276:289–297.
   Google Scholar
• GOPALAKRISHNAN M, BUISSON B, TOUMA E et al.: Stableexpression and pharmacological properties of the hu-man a7 nicotinic acetylcholine receptor. Eur. J. Phar-macol. (1995) 290:237–246.
   PubMed Web of Science ®Google Scholar
• LINDSTROM J, SCHOEPFER R, WHITING P: Molecular studies of the neuronal nicotinic acetylcholine recep-tor family. Mol. Neurobiol. (1987) 1:281–337.
   PubMed Web of Science ®Google Scholar
• LUETJE CW, WADA K, ROGERS S et al.: Neurotoxins dis-tinguish between different neuronal nicotinic acetyl-choline receptor subunit combinations. J. Neurochem. (1990) 55:632–640.
   PubMed Web of Science ®Google Scholar
• HOUGHTLING R, DAVILA-GARDIA M, KELLAR K: Charac-terization of (-44311]epibatidine binding to nicotinic cholinergic receptors in rat and human brain. Mol. Pharmacol. (1995) 48:280–287.
   PubMed Web of Science ®Google Scholar
• PERRY D, KELLAR K: [311]Epibatidine labels nicotinic re-ceptors in rat brain-an autoradiographic study. J. Phar-macol. Exp. Ther. (1995) 275:1030–1034.
   PubMedGoogle Scholar
• LONG JP, CHIOU CY: Pharmacological testing methods for drugs acting on the peripheral nervous system. J. Pharm. Sci. (1970) 59:133–148.
   PubMedGoogle Scholar
• LUTHER M, SCHOEPFER R, WHITING P et al.: A muscle acetylcholine receptor is expressed in the human cerebellar medulloblastoma cell line TE671. J. Neurosci. (1989) 9:1082–1095.
   PubMed Web of Science ®Google Scholar
• LUKAS RJ: Pharmacological distinctions between func-tional nicotinic acetylcholine receptors on the PC12 rat phenochromocytoma and the TE671 human me-dulloblastoma. J Pharmacol Exp. Ther. (1989) 251:175–182.
   PubMedGoogle Scholar
• LUKAS RJ: Expression of ganglia-type nicotinic acetyl-choline receptors and nicotinic binding sites by cells of the IMR-32 human neuroblastoma clonal line. J. Pharmacol. Exp. Ther. (1993) 265:294–302.
   PubMed Web of Science ®Google Scholar
• MARKS MJ, FARNHAM DA, GRADY SR, COLLINS AC: Nico-tinic receptor function determined by stimulation of rubidium efflux from mouse brain synaptosomes. J. Pharmacol. Exp. Ther. (1993) 264:542–552.
   PubMed Web of Science ®Google Scholar
• SEGUELA P, WADICHE J, DINELEY-MILLER K, DANI JA, PATRICK JW: Molecular cloning, functional properties, and distribution of rat brain a7: a nicotinic cation channel highly permeable to calcium. J. Neurosci. (1993) 13:596–604.
   PubMed Web of Science ®Google Scholar
• RAPIER C, LUNT GG, WONNACOTT S: Nicotinic modula-tion of NI dopamine release from striatal synapto-somes: pharmacological characterization. J. Neurochem. (1990) 54:937–945.
   PubMedGoogle Scholar
• CLARKE PBS, SCHWARTZ RD, PAUL SM, PERT CB, PERT A:Nicotinic binding in rat brain: autoradiographic com-parison of [3H]acetylcholine, [3H]nicotine, and [12511a-bungarotoxin. j Neurosci. (1985) 5:1307–1315.
   PubMedGoogle Scholar
• MARKS MJ, STITZEL JA, ROMM E, WEHNER JM, COLLINSAC: Nicotinic binding sites in rat and mouse brain: comparison of acetylcholine, nicotine, and a-bungarotoxin. Mol. Pharmacol. (1986) 30:427–436.
   PubMed Web of Science ®Google Scholar
• HALVORSEN S, BERG DK: Identification of a nicotinicacetylcholine receptor on neurons using an a-neurotoxin than blocks receptor function. J. Neurosci. (1986) 6:3405–3412.
   PubMedGoogle Scholar
• GRADY SR, MARKS MJ, COLLINS AC: Desensitization ofnicotine-stimulated [3M-dopamine release from mouse striatal synaptosomes. J. Neurochem. (1994) 62:1390–1398.
   PubMed Web of Science ®Google Scholar
• PATRICK J, SÉQUÉLA P, VERNINO S, AMADOR M, LUETJE C, DANI JA: Functional diversity of neuronal nicotinic acetylcholine receptors. Prog. Brain Res. (1990) 98:113–120.
   Google Scholar
• MARKS MJ, GRADY SR, COLLINS AC: Downregulation ofnicotinic receptor function after chronic nicotine in-fusion. J. Pharmacol. Exp. Ther. (1993) 266:1268–1276.
   PubMed Web of Science ®Google Scholar
• AMAR M, THOMAS P, JOHNSON C, LUNT GG, WONNA-COTT S: Agonist pharmacology at a7 nicotinic recep-tor expressed in Xenopus oocytes. FEBS Letts. (1993) 327:284–288.
   PubMedGoogle Scholar
• LUKAS RJ: Heterogeneity of high-affinity nicotinic[3H]acetylcholine binding sites. J. Pharmacol Exp. Ther. (1990) 253:51–57.
   PubMedGoogle Scholar
• WANG G-K, MOLINARO S, SCHMIDT J: Ligand responsesof a-bungarotoxin binding sites from skeletal muscle and optic lobe of the chick. J. BioL Chem. (1978) 253:8507–8512.
   PubMedGoogle Scholar
• BRIMBLECOMBE RW: Drug actions at central nicotinicsites. In: Drug Actions on Cholinergic Systems. University Park Press, Baltimore (1974):191–214.
   Google Scholar
• STOLERMAN IP, GARCHA HS, MIRZA NR: Dissociationsbetween the locomotor stimulant and depressant ef-fects of nicotinic agonists in rats. Psychopharmacology (Berlin) (1995) 117:430–437.
   PubMedGoogle Scholar
• BRIONI JD, ARNERIC SP: Nicotinic receptor agonists fa-cilitate retention of avoidance training: participation of dopaminergic mechanisms. Behav. Neur. Biol. (1993) 59:57–62.
   PubMedGoogle Scholar
• REAVILL C, JENNER P, KUMAR R, STOLERMAN IP: High af-finity binding of [311]0-nicotine to rat brain mem-branes and its inhibition by analogues of nicotine. Neuropharmacology (1988) 27:235–241.
   PubMedGoogle Scholar
• WONNACOTT S: Neurotoxin probes for neuronal nico-tinic receptors. In: Neurotoxins and Their Pharmacologi-cal Implications. Jenner P (Ed.), Raven Press, New York (1987):209–231.
   Google Scholar
• GARVEY DS, WASICAK JT, ELLIOTT RL et al.: Ligands for brain cholinergic channel receptors: synthesis and in vitro characterization of novel isoxazoles and isothia-zoles as bioisosteric replacements for the pyridine ring in nicotine. J. Med. Chem. (1994) 37:4455–4463.
   PubMed Web of Science ®Google Scholar
• LIPPIELLO PM, FERNANDES KG: Identification of puta-tive high affinity nicotinic receptors on cultured corti-cal neurons./ Pharmacol. Exp. Ther. (1988) 246:409–416.
   PubMedGoogle Scholar
• REAVILL C, JENNER P, KUMAR R, STOLERMAN IP: High af-finity binding of [3H]- 69-nicotine to rat brain mem-branes and its inhibition by analogues of nicotine. Neuropharmacology (1988) 27:235–241.
   PubMedGoogle Scholar
• GARVEY DS, WASICAK JT, DECKER MW et al.: Novelisoxazoles which interact with brain cholinergic channel receptors have intrinsic cognitive enhancing and amdolytic activities. J. Med. Chem. (1994) 37:1055–1059.
   PubMed Web of Science ®Google Scholar
• •Disclosure of ABT-418, the first potent nicotinic receptor agonist from isoxazole series.
   Google Scholar
• BARLOW RB, HAMILTON JT: Effects of some isomers and analogues of nicotines on junctional transmis-sion. Br. J. Pharmacol. Chemother. (1962) 18:510–542.
   PubMedGoogle Scholar
• CASTAGNOLI N, JR, MELIKIAN AP, ROSNATI V: The syn-thesis of pyrrolidine-substituted nicotine analogs. J. Pharm. ScL (1969) 58:860–863.
   PubMedGoogle Scholar
• ERDTMAN H, HAGLID F, WELLINGS I: Synthetic ana-logues of nicotine. I. Acta Chem. Scand. (1963) 17:1717–1726.
   Google Scholar
• HAGLID F: Studies on pyridine alkaloids and their ana-logues. Acta Pharm. Suecica A (1967) 4:117–138.
   PubMedGoogle Scholar
• HANKINS W, BURGER A: Pyrrolidine-substituted nico-tine analogs: synthesis and pharmacology. J. Pharm. ScL (1970) 59:342–343.
   PubMedGoogle Scholar
• LEETE E, LEETE SA: Synthesis of 4-methylnicotine and examination of its possible biosynthesis from 4-methyl nicotinic acid in 1Vicotiana tabacum. J. Org. Chem. (1978) 43:2122–2135.
   Google Scholar
• RONDAHL L: Synthetic analogues on nicotine. VI. Acta Pharm. Suecica (1977) 14:113–118.
   PubMedGoogle Scholar
• SACAAN Al, REID RT, SANTORI PA et al: Pharmacologi-cal characterization of SIB-1765F: a novel cholinergic ion channel agonist. j Pharmacol. Exp. Ther. (1997) 280:373–383.
   PubMedGoogle Scholar
• COSFORD NDP, BLEICHER L, HERBAUT A et al.: (S)-(-)-5-Ethyny1-3- (1-methyl-2-pyrrolidiny0 pyridine maleate (SIB-1508Y): a novel anti-parkinsonian agent with selectivity for neuronal nicotinic acetylcholine receptors. J. Med. Chem. (1996) 39:3235–3237.
   PubMedGoogle Scholar
• •Disclosure of pyridine-modified nicotine as a novel anti-Parkinson agents.
   Google Scholar
• CHAVEZ-NORIEGA LE, CRONA JH, WASHBURN MS, UR-RUTIA A, ELLIOTT KJ, JOHNSON EC: Pharmacological characterization of recombinant human neuranal nicotinic acetylcholine receptors ha262, ha264, ha362, ha4132, ha4134 and ha7 expressed in Xenopus oocytes. J. Pharmacol. Exp. Ther. (1997) 280:346–356.
   PubMed Web of Science ®Google Scholar
• MCDONALD IA, VERNIER J-M, CONSFORD N, COREY-NAEVE J: Neuronal nicotinic acetylcholine receptor agonists. Curr. Pharm. Design (1996) 2:357–366.
   Google Scholar
• •An overview on the molecular biology of nAChRs, the devel-opment of cell-based functional assay and the identification of SIB-1926 and SIB-1508Y using functional assays.
   Google Scholar
• LIN N-H, CARRERA GM, Jr., ANDERSON DJ: Synthesis and evaluation of nicotine analogs as neuronal nicotinic acetylcholine receptor ligands. J. Med. Chem. (1994) 37:3542–3553.
   PubMed Web of Science ®Google Scholar
• ELLIOTT RL, RYTHER KB, ANDERSON DJ et al: Phenyl pyrrolidine analogues as potent nicotinic acetylcho-line receptor ligands. Bioorg. Med. Chem. Lett. (1995) 5 (9):991–996.
   Google Scholar
• DUKAT M, FIEDLER W, DUMAS II et al.: Pyrrolidine-modified and 6-substituted analogs of nicotine. Eur. J. Med. Chem. (1996) 31:875–888.
   Web of Science ®Google Scholar
• CHAVADARIAN CG, SEEMAN JI, WOOTEN JB: Bridged nicotines. synthesis of cis-2,3,3a,4,5,9b-hexahydro-1-methyl-1H-pyrrolo[2,34]quinoline. J. Org. Chem. (1983) 48:492–494.
   Google Scholar
• GLASSCO W, SUCHOCKI J, GEORGE C, MARTIN BR, MAYEL: Synthesis, optical resolution, absolute configuration and preliminary pharmacology of (+) and (-)- cis-2,3,3a,4,5,9b-hexahydro-1 -methyl-1H-pyrrolo [3,2-h]isoquinoline, a structural analog of nicotine. J. Med. Chem. (1993) 36:3381–3385.
   PubMed Web of Science ®Google Scholar
• DAMAJ MGW, DUKAT M, MAY EL, GLENNON RA, MARTIN BR: Pharmacology of novel nicotinic analogs. Drug. Dev. Res. (1996) 38:177–187.
   Google Scholar
• GLENNON RA, MAAROUF A, FAHMY S et al.: Structure-affinity relationships of simple nicotine analogs. Med. Chem. Res. (1993) 2:546–551.
   Google Scholar
• HAGLID F, WELLINGS I: Synthetic analogues of nico-tine. II. Acta Chem. Scand. (1963a) 17:1727–1734.
   Google Scholar
• BENCHERIF M, LOVETETE ME, FOWLER KW et al.: Nico-tinic agonist with CNS selectivity. I. In vitro characteri-zation. J. Pharmacol Exp. Ther. (1996) 279:1413–1421.
   PubMedGoogle Scholar
• LIPPIELLO PM, BENCHERIF M, CALDWELL WS et al.: RJR-2403: a CNS selective nicotinic agonist with therapeu-tic potential. In: Alzheimer Disease from Molecular Biology to Therapy. Becker R, Giacobini E (Ed.), Birkhauser, Boston (1996) :281–286.
   Google Scholar
• •An overview on the biological profile of RJR-2403.
   Google Scholar
• LIPPIELLO PM, BENCHERIF M, GRAY JA et al.: RJR-2403: A nicotinic agonist with CNS selectivity II. In vivo charac-terization. J. Pharmacol. Exp. Ther. (1996) 279:1422–1429.
   PubMed Web of Science ®Google Scholar
• SUMMERS KL, LIPPIELO P, GIACOBINI E: A microdialysis study of the effects of the nicotinic agonist RJR-2403 on cortical release of acetylcholine and biogenic amines. Neurochem. Res. (1996) 21:1181–1186.
   PubMedGoogle Scholar
• WILSON KL, Jr., CHANG RSL, BOWMAN ER, MCKENNIS H, Jr.: Nicotine-like actions of cis-metanicotine and trans-metanicotine. J. Pharmacol. Exp. Ther. (1976) 196:685–696.
   Google Scholar
• FUJITA T, NAKAJIMA M, SOEDA Y, YAMAMOTO I: Physi-cochemical properties of biological interest and struc-ture of nicotine and its related compounds. Pestic. Biochem. Physiol. (1971) 1:151–162.
   Google Scholar
• KAMIMURA H, MATSUMOTO A, MIYAZAKI Y, YAMA-MOTO I: Studies on nicotinoids as an insecticide. Part IV. Relation of structure to toxicity of pyridylmethyl-amines. Agr. Biol Chem. (1963) 27:684–688.
   Web of Science ®Google Scholar
• YAMAMOTO I, SOEDA Y, KAMIMURA H, YAMAMOTO R: Studies on nicotinoids as an insecticide. Part VII. Cho-linesterase inhibition by nicotinoids and pyridylal-kylamines - its significance to mode of action. Agr. Biol Chem. (1968) 32:1341–1348.
   Google Scholar
• ACHESON RM, FERRIS MJ, SINCLAIR NM: Transforma-tions involving the pyrrolidine ring of nicotine. J. Chem. Soc. Perkin Trans. 1(1980) 2:579-585.
   Google Scholar
• MURAHASHI S-I, WANTANABE T: Palladium catalyzed hydrolysis of tertiary amines with water. J. Am. Chem. Soc. (1979) 101:7429–7430.
   Google Scholar
• KEM WR: Structure and action of nemertine toxins. Am. Zoology (1985) 25:99–111.
   Google Scholar
• COLLINS AC, BHAT RV, PAULY JR, MARKS MJ: Modulation of nicotinic receptors by chronic exposure to nico-tinic agonists and antagonists. In: The Biology of Nicotine Dependence. Ciba Foundation Symposia. Bock G, Marsh J (Ed.), John Wiley & Sons, West Sussex (199068–86.
   Google Scholar
• DE FIEBRE CM, MEYER EM, HENRY JC, MURASKIN SI, KEM WR, PAPKE RL: Characterization of a series of anabaseine-derived compounds reveals that the 3-(4)-dimethylaminocinnamylidine derivative (DMAC) is a selective agonist at neuronal a7/[12511a-bu-ngarotoxin receptor subtypes. Mol. Pharmacol (1995) 47:164–171.
   PubMed Web of Science ®Google Scholar
• ARENDASH GW, SENGSTOCK GJ, SANBERG PR, KEM WR: Improved learning and memory in aged rats with chronic administration of the nicotinic receptor ago-nist GTS-21. Brain Res. (1995) 646:252–259.
   Google Scholar
• MARTIN EJ, PANICKAR KS, KING MA et al.: Cytoprotec-tive actions of 2,4-dimethoxybenzylidene anabaseine in differentiated PC12 cells and septal cholinergic neu-rons. Drug Dev. Res. (1994) 31:135–141.
   Web of Science ®Google Scholar
• BRIGGS CA, MCKENNA DG, PIATTONI-KAPLAN M: Hu-man a-7 nicotinic acetylcholine receptor response to novel ligands. Neuropharmacology (1995) 34:583–590.
   PubMed Web of Science ®Google Scholar
• BRIGGS CA, ANDERSON D, BRIONI JD et al: Functional characterization of the novel neuronal nicotinic ace-tylcholine receptor ligand GTS-21 in vitro and in vivo. Pharmacol. Biochem. Behav. (1997) 57:231–241.
   PubMed Web of Science ®Google Scholar
• KEM WR, MAHNIR VM, LIN B: Interaction of DMXBA(GTS-21), a cognition-enhancing compound, with cho-linergic receptors. Soc. Neurosci. Abs. (1994) 20:1134–1467.
   Google Scholar
• MEYER EM, DE FIEBRE CM, HUNTER BE et al.: Effects of anabaseine-related analogs on rat brain nicotinic re-ceptor binding and on avoidance behaviors. Drug Dev. Res. (1994) 31:127–134.
   Web of Science ®Google Scholar
• WOODRUFF-PAK DS, LI Y-T, KEM WR: A nicotinic ago-nist (GTS-21), eyeblink classical conditioning, and nicotinic receptor binding in rabbit brain. Brain Res. (1994) 645:309–317.
   PubMed Web of Science ®Google Scholar
• KEM WR, MAHNIR VM, LIN B, PROKAI-TARTRAI K: Twoprimary GTS-21 metabolites are potent partial ago-nists at alpha 7 nicotinic receptors expressed in the Xenopus oocyte. Soc. Neurosci. Abs. (1996) 22. Abstract 110.7.
   Google Scholar
• SPANDE TF, GARAFFO HM, EDWARDS MW, YEH HJC, PANNELL L, DALY JW: Epibatidine: a novel (chloropyri-dy0 azabicycloheptane with potent analgesic activity from an ecuadoran poison frog. J. Am. Chem. Soc. (1992) 114:3475–3478.
   Web of Science ®Google Scholar
• •Disclosure of the structure of epibatidine and its potent anal-gesic activity.
   Google Scholar
• GERZANISH V, PENG X, WANG F et al.: Comparative pharmacology of epibatidine: a potent agonist. Mol. Pharmacol. (1995) 48:774–782.
   PubMedGoogle Scholar
• SULLIVAN JP, DECKER MW, BRIONI JD et al.: (+)-Epibat-idine elicits a diversity of in vitro and in vivo effects mediated by nicotinic acetylcholine receptors. J. Phar-macol. Exp. Ther. (1994) 271:624–631.
   PubMed Web of Science ®Google Scholar
• BADIO B, DALY JW: Epibatidine, a potent analgetic andnicotinic agonist. Mol. Pharmacol. (1994) 45:563–569.
   PubMed Web of Science ®Google Scholar
• SULLIVAN JP, BRIGGS CA, DONNELLY-ROBERTS D et al.: (+)-Epibatidine can differentially evoke responses me-diated by putative subtypes of nicotinic acetylcholine receptors (nAChRs). Med. Chem. Res. (1994) 4:502–516.
   Google Scholar
• DAMAJ MI, CREASY KR, GROVE AD, ROSECRANS JA, MAR-TIN BR: Pharmacological effects of epibatidine optical enantiomers. Brain Res. (1994) 664:34–40.
   PubMed Web of Science ®Google Scholar
• SENOKUCHI K, NAKAI H, KAWAMURA M et al.: Synthesis and biological evaluation of (±)-epibatidine and the congeners. Syn. Lett. (1994) 5:343–344.
   Google Scholar
• LIN N-H, HE Y, ANDERSON DJ et al.: Synthesis and structure-activity relationships of pyrrolidine-modified analogs of the potent cholinergic channel ac-tivator, ABT 418. Bioorg. Med. Chem. Lett. (1994) 4:2389–2394.
   Google Scholar
• LIN N-H, HE Y, ARNERIC SP, SULLIVAN JP: Synthesis and structure-activity relationships of 2'-(R) and (S)-pyrrolidine-modified analogs of the cholinergic channel activator, ABT-418. Bioorg. Med. Chem. Lett. (1995) 5:1141–1146.
   Web of Science ®Google Scholar
• ARNERIC SP, SULLIVAN JP, BRIGGS CA et al.: (S)-3-Methyl-5-(1-methyl-2-pyrrolidinyl) isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities. I. In vitro charac-terization. J. Pharmacol. Exp. Ther. (1994) 270:310–318.
   PubMed Web of Science ®Google Scholar
• WILLIAMS M, SULLIVAN JP, ARNERIC SP: Neuronal nico-tinic acetylcholine receptors. Drug News Perspect. (1994) 7:205–223.
   Google Scholar
• ••Extensive review on the nAChRs and their therapeuticpotentials.
   Google Scholar
• DECKER MW, BRIONI JD, SULLIVAN JP et al.: (S)-3-Methyl-5-(1-methyl-2-pyrrolidinyl) isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities. II. In vivo charac-terization. J. Pharmacol. Exp. Ther. (1994) 270:319–328.
   PubMedGoogle Scholar
• DONNELLY-ROBERTS DL, XUE IC, ARNERIC SP, SULLIVAN JP: In vitro neuroprotective properties of the novel cholinergic channel activator (ChCA), ABT-418. Brain Res. (1996) 719:36–44.
   PubMed Web of Science ®Google Scholar
• WILLIAMS M, DAVIS RE: Alzheimer's disease and related dementias: prospects for treatment. Exp. Opin. Invest. Drugs (1997) 6:735–757.
   PubMedGoogle Scholar
• ••Comprehensive overview summarising recent develop-ments on the molecular approach to AD therapy.
   Google Scholar
• LIN N-H, HEY, KOPEKA H: A short, efficient synthesis of the novel cholinergic channel activator, ABT-418, form L-pyroglutamic acid. Tetra. Lett. (1995) 36:2563.
   Google Scholar
• ELLIOTT RE, KOPEKA H, LIN N-H, HE Y, GARVEY DS: A short, efficient synthesis of the novel cholinergic channel activator, ABT-418, form L-proline. Synthesis (1995) 7:771–774.
   Google Scholar
• ABOOD LG, GRASSI S: [311]Methylcarbamylcholine, a new radioligand for studying brain nicotinic recep-tors. Biochem. Pharmacol (1986) 35:4199–4202.
   PubMedGoogle Scholar
• ABOOD LG, LERNER-MARMAROSH N, WANG D, SARAS-WATI M Structure-activity relationships of various nicotinoids and N-substituted carbamate esters of choline and other amino alcohols. Med. Chem. Res. (1993) 2:552–563.
   Google Scholar
• ANDERSON DJ, ARNERIC SP: Nicotinic receptor binding of [311]cytisine, [311]nicotine and rlilmethylcarbamyl-choline in rat brain. Eur. j Pharmacol. (1994) 253:261–267.
   PubMed Web of Science ®Google Scholar
• MACALLAN DRE, LUNT GG, WONNACOTT S et al.: Meth-yllycaconitine and (+)-anatoxin-a differentiate be-tween nicotinic receptors in vertebrate and invertebrate nervous systems. FEBS Letts. (1988) 226:357–363.
   PubMedGoogle Scholar
• SWANSON KL, ARONSTAM RS, WONNACOTT S, RAPO-PORT H, ALBUQUERQUE EX: Nicotinic pharmacology of anatoxin analogs. I. Side chain structure-activity re-lationships at peripheral agonist and noncompetitive antagonist sites. J. Pharmacol Exp. Ther. (1991) 259:377–386.
   Google Scholar
• WONNACOTT S, JACKMAN S, SWANSON KL, RAPOPORT H, ALBUQUERQUE EX: Nicotinic pharmacology of ana-toxin analogs. II. Side chain structure-activity relation-ships at neuronal nicotinic ligand binding sites. J. Pharmacol. Exp. Ther. (1991) 259:387–391.
   Google Scholar
• THOMAS PB, GALLAGHER T, WONNACOTT S: Alkyl-modified side chain variants of anatoxin-a: a series of potent nicotinic agonists. Drug Dev. Res. (1994) 31:147–156.
   Web of Science ®Google Scholar
• THOMAS P, STEPHENS M, AMAR M et al.: (+)-Anatoxin is a potent agonist at neuronal nicotinic acetylcholine receptors. J. Neurochem. (1993) 60:2308–2311.
   PubMed Web of Science ®Google Scholar
• DALY JW, NISHIZAWA Y, EDWARDS MW, WATERS JA, AR-ONSTAM RS: Nicotinic receptor-elicited sodium flux in rat pheochromocytoma PC12 cells: effects of agonists, antagonists, and noncompetitive blockers. Neurochem. Res. (1991) 16:489–500.
   PubMed Web of Science ®Google Scholar
• BARLOW RB, MCLEOD LJ: Some studies on cytisine and its methylated derivatives. Br. J. Pharmacol. (1969) 35:161–174.
   PubMed Web of Science ®Google Scholar
• ABREO MA, UN N-H, GARVEY DS et al.: Novel 3-pyridyl ethers with subnanomolar affinity for central nico-tinic acetylcholine receptors. J. Med. Chem. (1996) 39:817–825.
   PubMedGoogle Scholar
• •Disclosure of potent and selective nAChR agonists, espe-cially focused on the in vitro profile of A-85380.
   Google Scholar
• UN N-H, GUNN DE, RYTHER KB et al.: Structure-activity studies on 2-methyl-3-(2 (S)-pyrrolidiny-lmethoxy)pyridine (ABT-089): an orally bioavailable 3-pyridyl ether nicotinic acetylcholine receptor ligand with cognition-enhancing properities. J. Med. Chem. (1997) 40:385–390.
   PubMedGoogle Scholar
• •Characterisation of in vitro and in vivo profiles of ABT-089.
   Google Scholar
• BRIONI JD, MORGAN SL, O'NEILL AB eta].: In vivo profile of novel nicotinic ligands with CNS selectivity. Med. Chem. Res. (1996) 6:487–510.
   Google Scholar
• ARNERIC SP, BANNON AW, BRIONI JD et al.: ABT-089: an orally effective cholinergic channel modulator (ChCM) with cognitive enhancement and neuropro-tective action. In: Alzheimer's Disease: From Molecular Biology to Therapy. Becker B, Giacobini E (Ed.), Birkhauser, Boston (1996).
   Google Scholar
• SULLIVAN JP, DONNELLY-ROBERTS D, BRIGGS CA et al.: ABT-089 [2-methyl-3-(2- (S)-pyrrolidinylmethoxy) pyridine dihydrochloride]: a potent and selective cho-linergic channel modulator with cytoprotective prop-erties. J. Pharmacol. Exp. Ther. (1997) 283:235–246.
   PubMed Web of Science ®Google Scholar
• DECKER MW, BANNON AW, CURZON P eta].: ABT-089[2-methy1-3- (2- (S)-pyrrolidinylmethoxy)pyridine dihy-drochloride]: II. A novel cholinergic channel modula-tor with effects on cognitive performance in rats and monkeys. J. Pharmacol Exp. Ther. (1997) 283:247–258.
   Google Scholar
• HOLLADAY MW, WASICAK JT, LIN N-H et al.: Identifica-tion and structure-activity relationships of (R)-5-(2-azetidinylmethoxy)-2-chloropyridine (ABT-594), a po-tent, orally active non-opiate analgesic agent acting via neuronal nicotinic acetylcholine receptors. J. Med. Chem. (1998) 41:407–412.
   PubMed Web of Science ®Google Scholar
• •SAR studies on nAChR agonists as analgesic agents and in vi-tro profile of ABT-594.
   Google Scholar
• BANNON AW, DECKER MW, CURZON P et al.: 5-( (2R)-azetidinylmethoxy)-2-chloropyridine [ABT-594]: a novel orally effective antinociceptive agent act-ing via neuronal nicotinic acetylcholine receptors. II. In vivo characterization. J. Pharmacol. Exp. Ther. (1998) 285:787–794.
   PubMedGoogle Scholar
• BANNON AW, DECKER MW, HOLLADAY MW et al.: Broad-spectrum, non-opiod analgesic activity by selec-tive modulation of neuronal nicotinic acetylcholine receptors. Science (1998) 279:77–81.
   PubMed Web of Science ®Google Scholar
• ARNERIC SP, SULLIVAN JP, WILLIAMS M: Neuronal nico-tinic acetylcholine receptors: novel targets for CNS therapeutics. In: Psychopharmacology: Fourth Generation of Progress. Bloom FE, Kupfer DJ (Ed.), Raven Press, New York (1995).
   Google Scholar
• ARNERIC SP, HOLLADAY MW, SULLIVAN JP: Cholinergic channel modulators as a novel therapeutic strategy for Alzheimer's disease. Exp. Opin. Invest. Drugs (1996) 5:79–100.
   Google Scholar
• SCHNEIDER F, OLSSON T: Clinical experience with lo-beline as a smoking cessation agent. Med. Chem. Res. (1996) 6:562–570.
   Google Scholar